If you made any changes in Pure these will be visible here soon.

Research Output 1998 2019

Filter
Article
2013

A phase II study of cisplatin /S-1 in patients with carcinomas of unknown primary site

Tsuya, A., Kurata, T., Tamiya, A., Okamoto, I., Ueda, S., Sakai, D., Sugimoto, N., Matsumoto, K., Goto, I., Yamamoto, N., Fukuoka, M. & Nakagawa, K., Dec 1 2013, In : Investigational New Drugs. 31, 6, p. 1568-1572 5 p.

Research output: Contribution to journalArticle

Cisplatin
Carcinoma
Combination Drug Therapy
Appointments and Schedules
Febrile Neutropenia
1 Citation (Scopus)

A phase i study of S-1 with concurrent radiotherapy in elderly patients with locally advanced non-small cell lung cancer

Hasegawa, Y., Okamoto, I., Takezawa, K., Miyazaki, M., Tsurutani, J., Yonesaka, K., Morinaga, R., Tsuya, A., Terashima, M., Kudoh, T., Azuma, K., Kurata, T., Nishikawa, T., Fukuoka, M., Nishimura, Y. & Nakagawa, K., Jun 1 2013, In : Investigational New Drugs. 31, 3, p. 599-604 6 p.

Research output: Contribution to journalArticle

Non-Small Cell Lung Carcinoma
Radiotherapy
Thorax
Stomatitis
Pneumonia
1 Citation (Scopus)

Bronchoscopic findings for bevacizumab-related pulmonary hemorrhage in advanced non-small cell lung cancer

Okamoto, K., Okamoto, I., Miyazaki, M., Tanaka, K., Kaneda, H. & Nakagawa, K., Oct 1 2013, In : Investigational New Drugs. 31, 5, p. 1364-1366 3 p.

Research output: Contribution to journalArticle

Bronchoscopy
Non-Small Cell Lung Carcinoma
Hemorrhage
Lung
Hemoptysis
58 Citations (Scopus)
Lung Neoplasms
Central Nervous System
Radiotherapy
Non-Small Cell Lung Carcinoma
Disease Progression
12 Citations (Scopus)

Clinical response to crizotinib retreatment after acquisition of drug resistance

Matsuoka, H., Kurata, T., Okamoto, I., Kaneda, H., Tanaka, K. & Nakagawa, K., Jul 1 2013, In : Journal of Clinical Oncology. 31, 19

Research output: Contribution to journalArticle

Fusion Oncogene Proteins
Serine Endopeptidases
Neoplasm Drug Resistance
Drug Administration Schedule
Antineoplastic Combined Chemotherapy Protocols
35 Citations (Scopus)

Efficacy and safety analysis according to histology for s-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer: Updated results of the west japan oncology group lets study

Yoshioka, H., Okamoto, I., Morita, S., Ando, M., Takeda, K., Seto, T., Yamamoto, N., Saka, H., Atagi, S., Hirashima, T., Kudoh, S., Satouchi, M., Ikeda, N., Iwamoto, Y., Sawa, T., Nakanishi, Y. & Nakagawa, K., May 1 2013, In : Annals of Oncology. 24, 5, p. 1326-1331 6 p., mds629.

Research output: Contribution to journalArticle

Carboplatin
Non-Small Cell Lung Carcinoma
Histology
Japan
Safety
25 Citations (Scopus)

Efficacy and safety of weekly nab-paclitaxel plus carboplatin in patients with advanced non-small cell lung cancer

Satouchi, M., Okamoto, I., Sakai, H., Yamamoto, N., Ichinose, Y., Ohmatsu, H., Nogami, N., Takeda, K., Mitsudomi, T., Kasahara, K. & Negoro, S., Jul 1 2013, In : Lung Cancer. 81, 1, p. 97-101 5 p.

Research output: Contribution to journalArticle

Carboplatin
Non-Small Cell Lung Carcinoma
Safety
Paclitaxel
Thrombocytopenia
24 Citations (Scopus)

Histology and smoking status predict survival of patients with advanced non-small-cell lung cancer: Results of west Japan oncology group (WJOG) study 3906L

Kogure, Y., Ando, M., Saka, H., Chiba, Y., Yamamoto, N., Asami, K., Hirashima, T., Seto, T., Nagase, S., Otsuka, K., Yanagihara, K., Takeda, K., Okamoto, I., Aoki, T., Takayama, K., Yamasaki, M., Kudoh, S., Katakami, N., Miyazaki, M. & Nakagawa, K., Jan 1 2013, In : Journal of Thoracic Oncology. 8, 6, p. 753-758 6 p.

Research output: Contribution to journalArticle

Non-Small Cell Lung Carcinoma
Histology
Japan
Smoking
Adenocarcinoma
17 Citations (Scopus)

Human papillomavirus DNA and p16 expression in Japanese patients with oropharyngeal squamous cell carcinoma

Kawakami, H., Okamoto, I., Terao, K., Sakai, K., Suzuki, M., Ueda, S., Tanaka, K., Kuwata, K., Morita, Y., Ono, K., Nishio, K., Nishimura, Y., Doi, K. & Nakagawa, K., Jan 1 2013, In : Cancer Medicine. 2, 6, p. 933-941 9 p.

Research output: Contribution to journalArticle

Squamous Cell Carcinoma
DNA
p16 Genes
Methylation
Cisplatin
64 Citations (Scopus)

MET amplification as a potential therapeutic target in gastric cancer

Kawakami, H., Okamoto, I., Arao, T., Okamoto, W., Matsumoto, K., Taniguchi, H., Kuwata, K., Yamaguchi, H., Nishio, K., Nakagawa, K. & Yamada, Y., Jan 1 2013, In : Oncotarget. 4, 1, p. 9-17 9 p.

Research output: Contribution to journalArticle

Stomach Neoplasms
Protein-Tyrosine Kinases
Therapeutics
Polymerase Chain Reaction
Gene Dosage
24 Citations (Scopus)

Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naïve patients with advanced nonsquamous non-small-cell lung cancer

Okamoto, I., Aoe, K., Kato, T., Hosomi, Y., Yokoyama, A., Imamura, F., Kiura, K., Hirashima, T., Nishio, M., Nogami, N., Okamoto, H., Saka, H., Yamamoto, N., Yoshizuka, N., Sekiguchi, R., Kiyosawa, K., Nakagawa, K. & Tamura, T., Jan 1 2013, In : Investigational New Drugs. 31, 5, p. 1275-1282 8 p.

Research output: Contribution to journalArticle

Pemetrexed
Carboplatin
Non-Small Cell Lung Carcinoma
Epidermal Growth Factor Receptor
Therapeutics
29 Citations (Scopus)

Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms

Li, J., Bennett, K., Stukalov, A., Fang, B., Zhang, G., Yoshida, T., Okamoto, I., Kim, J. Y., Song, L., Bai, Y., Qian, X., Rawal, B., Schell, M., Grebien, F., Winter, G., Rix, U., Eschrich, S., Colinge, J., Koomen, J., Superti-Furga, G. & 1 others, Haura, E. B., Nov 5 2013, In : Molecular Systems Biology. 9, 705.

Research output: Contribution to journalArticle

Growth Factors
resistance mechanisms
Vulnerability
Epidermal Growth Factor Receptor
Receptor
8 Citations (Scopus)

Phase 2 study of S-1 and carboplatin plus bevacizumab followed by maintenance S-1 and bevacizumab for chemotherapy-naive patients with advanced nonsquamous non-small cell lung cancer

Urata, Y., Okamoto, I., Takeda, M., Hattori, Y., Okuno, K., Shimada, T., Kurata, T., Kaneda, H., Miyazaki, M., Terashima, M., Tanaka, K., Morita, S., Nakagawa, K., Negoro, S. & Satouchi, M., Jun 15 2013, In : Cancer. 119, 12, p. 2275-2281 7 p.

Research output: Contribution to journalArticle

Carboplatin
Non-Small Cell Lung Carcinoma
Maintenance
Drug Therapy
Disease Progression
5 Citations (Scopus)

Phase i and pharmacokinetic study of gefitinib and S-1 combination therapy for advanced adenocarcinoma of the lung

Kiyota, H., Okamoto, I., Takeda, M., Daga, H., Naito, T., Miyazaki, M., Okada, H., Hayashi, H., Tanaka, K., Terashima, M., Azuma, K., Murakami, H., Takeda, K., Yamamoto, N. & Nakagawa, K., Apr 1 2013, In : Cancer Chemotherapy and Pharmacology. 71, 4, p. 859-865 7 p.

Research output: Contribution to journalArticle

Pharmacokinetics
Therapeutics
Chemotherapy
Aspartate Aminotransferases
Disease-Free Survival
8 Citations (Scopus)

Phase II study of bi-weekly irinotecan for patients with previously treated HER2-negative metastatic breast cancer: KMBOG0610B

Hayashi, H., Tsurutani, J., Satoh, T., Masuda, N., Okamoto, W., Morinaga, R., Terashima, M., Miyazaki, M., Okamoto, I., Nishida, Y., Tominaga, S., Tokunaga, Y., Yamaguchi, M., Sakamoto, J., Nakayama, T. & Nakagawa, K., Apr 1 2013, In : Breast Cancer. 20, 2, p. 131-136 6 p.

Research output: Contribution to journalArticle

irinotecan
Breast Neoplasms
Anthracyclines
Taxoids
Topoisomerase I Inhibitors
1 Citation (Scopus)

Phase I pharmacokinetic study of S-1 granules and nedaplatin for advanced head and neck cancer

Hayashi, H., Okamoto, I., Ueda, S., Tanaka, K., Okamoto, K., Kawakami, H., Nishina, S., Takeda, M., Fujisaka, Y., Satoh, T., Terao, K., Nishimura, Y., Doi, K. & Nakagawa, K., Dec 1 2013, In : Anticancer research. 33, 12, p. 5699-5706 8 p.

Research output: Contribution to journalArticle

Head and Neck Neoplasms
Pharmacokinetics
Neutropenia
Endpoint Determination
nedaplatin
12 Citations (Scopus)

Postprogression survival for first-line chemotherapy in patients with advanced gastric cancer

Kawakami, H., Okamoto, I., Hayashi, H., Taguri, M., Morita, S. & Nakagawa, K., Sep 1 2013, In : European Journal of Cancer. 49, 14, p. 3003-3009 7 p.

Research output: Contribution to journalArticle

Stomach Neoplasms
Drug Therapy
Survival
Disease-Free Survival
19 Citations (Scopus)

Postprogression survival in patients with advanced non-small-cell lung cancer who receive second-line or third-line chemotherapy

Hayashi, H., Okamoto, I., Taguri, M., Morita, S. & Nakagawa, K., Jul 15 2013, In : Clinical Lung Cancer. 14, 3, p. 261-266 6 p.

Research output: Contribution to journalArticle

Non-Small Cell Lung Carcinoma
Drug Therapy
Survival
Disease-Free Survival
Therapeutics
229 Citations (Scopus)

Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial

Hironaka, S., Ueda, S., Yasui, H., Nishina, T., Tsuda, M., Tsumura, T., Sugimoto, N., Shimodaira, H., Tokunaga, S., Moriwaki, T., Esaki, T., Nagase, M., Fujitani, K., Yamaguchi, K., Ura, T., Hamamoto, Y., Morita, S., Okamoto, I., Boku, N. & Hyodo, I., Dec 10 2013, In : Journal of Clinical Oncology. 31, 35, p. 4438-4444 7 p.

Research output: Contribution to journalArticle

irinotecan
Paclitaxel
Combination Drug Therapy
Platinum
Stomach Neoplasms
42 Citations (Scopus)
Pyrazoles
Pyridines
Bone Neoplasms
X Ray Computed Tomography
Gene Rearrangement
48 Citations (Scopus)

Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer

Socinski, M. A., Okamoto, I., Hon, J. K., Hirsh, V., Dakhil, S. R., Page, R. D., Orsini, J., Yamamoto, N., Zhang, H. & Renschler, M. F., Sep 1 2013, In : Annals of Oncology. 24, 9, p. 2390-2396 7 p., mdt235.

Research output: Contribution to journalArticle

Carboplatin
Non-Small Cell Lung Carcinoma
Histology
Safety
Paclitaxel
79 Citations (Scopus)

Safety and efficacy of weekly nab ® -paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer

Socinski, M. A., Langer, C. J., Okamoto, I., Hon, J. K., Hirsh, V., Dakhil, S. R., Page, R. D., Orsini, J., Zhang, H. & Renschler, M. F., Feb 1 2013, In : Annals of Oncology. 24, 2, p. 314-321 8 p., mds461.

Research output: Contribution to journalArticle

Carboplatin
Non-Small Cell Lung Carcinoma
Safety
Disease-Free Survival
Paclitaxel
33 Citations (Scopus)

Severe acute interstitial lung disease after crizotinib therapy in a patient with EML4-ALK-positive non-small-cell lung cancer

Tamiya, A., Okamoto, I., Miyazaki, M., Shimizu, S., Kitaichi, M. & Nakagawa, K., Jan 1 2013, In : Journal of Clinical Oncology. 31, 1

Research output: Contribution to journalArticle

Fusion Oncogene Proteins
Pyrazoles
Pyridines
X Ray Computed Tomography
Fatal Outcome
11 Citations (Scopus)

Sorting nexin 2-mediated membrane trafficking of c-Met contributes to sensitivity of molecular-targeted drugs

Ogi, S., Fujita, H., Kashihara, M., Yamamoto, C., Sonoda, K., Okamoto, I., Nakagawa, K., Ohdo, S., Tanaka, Y., Kuwano, M. & Ono, M., May 1 2013, In : Cancer Science. 104, 5, p. 573-583 11 p.

Research output: Contribution to journalArticle

Sorting Nexins
Epidermal Growth Factor Receptor
Membranes
Pharmaceutical Preparations
Lung Neoplasms
2012

[Molecular-targeted drug for non-small cell lung cancer].

Okamoto, I., Jan 1 2012, In : Unknown Journal. 70 Suppl 8, p. 438-442 5 p.

Research output: Contribution to journalArticle

Fusion Oncogene Proteins
Anilides
Molecular Targeted Therapy
Pyrimidines
Non-Small Cell Lung Carcinoma
98 Citations (Scopus)

Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer

Tanizaki, J., Okamoto, I., Okabe, T., Sakai, K., Tanaka, K., Hayashi, H., Kaneda, H., Takezawa, K., Kuwata, K., Yamaguchi, H., Hatashita, E., Nishio, K. & Nakagawa, K., Nov 15 2012, In : Clinical Cancer Research. 18, 22, p. 6219-6226 8 p.

Research output: Contribution to journalArticle

Non-Small Cell Lung Carcinoma
Epidermal Growth Factor
Protein-Tyrosine Kinases
Lung Neoplasms
Epidermal Growth Factor Receptor
12 Citations (Scopus)

A novel mass spectrometry-based assay for diagnosis of EML4-ALK-positive non-small cell lung cancer

Sakai, K., Okamoto, I., Takezawa, K., Hirashima, T., Kaneda, H., Takeda, M., Matsumoto, K., Kimura, H., Fujita, Y., Nakagawa, K., Arao, T. & Nishio, K., Jan 1 2012, In : Journal of Thoracic Oncology. 7, 5, p. 913-918 6 p.

Research output: Contribution to journalArticle

Non-Small Cell Lung Carcinoma
Mass Spectrometry
Paraffin
Formaldehyde
Fluorescence In Situ Hybridization
57 Citations (Scopus)

Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification

Okamoto, W., Okamoto, I., Arao, T., Kuwata, K., Hatashita, E., Yamaguchi, H., Sakai, K., Yanagihara, K., Nishio, K. & Nakagawa, K., Jul 1 2012, In : Molecular Cancer Therapeutics. 11, 7, p. 1557-1564 8 p.

Research output: Contribution to journalArticle

Protein-Tyrosine Kinases
Stomach Neoplasms
X-Linked Inhibitor of Apoptosis Protein
Apoptosis
Inhibitor of Apoptosis Proteins
28 Citations (Scopus)

Association of the expression of mutant epidermal growth factor receptor protein as determined with mutation-specific antibodies in non-small cell lung cancer with progression-free survival after gefitinib treatment

Azuma, K., Okamoto, I., Kawahara, A., Taira, T., Nakashima, K., Hattori, S., Kinoshita, T., Takeda, M., Nakagawa, K., Takamori, S., Kuwano, M., Ono, M. & Kage, M., Jan 1 2012, In : Journal of Thoracic Oncology. 7, 1, p. 122-127 6 p.

Research output: Contribution to journalArticle

Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Disease-Free Survival
Mutation
Antibodies

Capecitabine plus cisplatin treatment for advanced gastric cancer in a patient with hepatic impairment secondary to metastases

Kawakami, H., Nishina, S. I., Ueda, S., Kudo, T., Okamoto, W., Kurata, T., Okamoto, I. & Nakagawa, K., May 1 2012, In : Gastrointestinal Cancer Research. 5, 3, p. 103-105 3 p.

Research output: Contribution to journalArticle

Cisplatin
Stomach Neoplasms
Neoplasm Metastasis
Liver
Therapeutics
13 Citations (Scopus)

Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC

Takeda, M., Okamoto, I., Tsurutani, J., Oiso, N., Kawada, A. & Nakagawa, K., Jun 1 2012, In : Japanese journal of clinical oncology. 42, 6, p. 528-533 6 p., hys042.

Research output: Contribution to journalArticle

Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Non-Small Cell Lung Carcinoma
Mutation
Interstitial Lung Diseases
31 Citations (Scopus)

Clinical outcome for EML4-ALK-positive patients with advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy

Takeda, M., Okamoto, I., Sakai, K., Kawakami, H., Nishio, K. & Nakagawa, K., Nov 1 2012, In : Annals of Oncology. 23, 11, p. 2931-2936 6 p., mds124.

Research output: Contribution to journalArticle

Platinum
Non-Small Cell Lung Carcinoma
Drug Therapy
Mutation
Oncogene Fusion
11 Citations (Scopus)

Clinical outcomes of thoracic radiotherapy for locally advanced nsclc with EGFR mutations or EML4-ALK rearrangement

Hayashi, H., Okamoto, I., Kimura, H., Sakai, K., Nishimura, Y., Nishio, K. & Nakagawa, K., Oct 2012, In : Anticancer Research. 32, 10, p. 4533-4538 6 p.

Research output: Contribution to journalArticle

erbB-1 Genes
Radiotherapy
Thorax
Non-Small Cell Lung Carcinoma
Mutation
10 Citations (Scopus)

Clinical phase I study of elpamotide, a peptide vaccine for vascular endothelial growth factor receptor 2, in patients with advanced solid tumors

Okamoto, I., Arao, T., Miyazaki, M., Satoh, T., Okamoto, K., Tsunoda, T., Nishio, K. & Nakagawa, K., Dec 1 2012, In : Cancer Science. 103, 12, p. 2135-2138 4 p.

Research output: Contribution to journalArticle

Vascular Endothelial Growth Factor Receptor-2
Subunit Vaccines
Vaccines
Maximum Tolerated Dose
Neoplasms
32 Citations (Scopus)

Combined effect of ALK and MEK inhibitors in EML4-ALK-positive non-small-cell lung cancer cells

Tanizaki, J., Okamoto, I., Takezawa, K., Sakai, K., Azuma, K., Kuwata, K., Yamaguchi, H., Hatashita, E., Nishio, K., Janne, P. A. & Nakagawa, K., Feb 14 2012, In : British journal of cancer. 106, 4, p. 763-767 5 p.

Research output: Contribution to journalArticle

Mitogen-Activated Protein Kinase Kinases
Non-Small Cell Lung Carcinoma
MAP Kinase Signaling System
Apoptosis
Phosphorylation
7 Citations (Scopus)

Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors

Okamoto, I., Shimizu, T., Miyazaki, M., Tsurutani, J., Ichikawa, Y., Terashima, M., Takeda, M., Fumita, S., Ohki, E., Kimura, N., Hashimoto, J. & Nakagawa, K., Apr 1 2012, In : Investigational New Drugs. 30, 2, p. 639-646 8 p.

Research output: Contribution to journalArticle

Pemetrexed
Feasibility Studies
Appointments and Schedules
Neoplasms
Platelet-Derived Growth Factor Receptors

General evidence for the efficacy of maintenance therapy

Tanaka, K. & Okamoto, I., 2012, In : Japanese Journal of Chest Diseases. 71, 10, p. 964-971 8 p.

Research output: Contribution to journalArticle

Non-Small Cell Lung Carcinoma
Maintenance
Therapeutics
Survival
9 Citations (Scopus)
docetaxel
Platinum
Non-Small Cell Lung Carcinoma
Disease Progression
Drug Therapy
48 Citations (Scopus)

Overcoming erlotinib resistance in EGFR mutation-positive non-small cell lung cancer cells by targeting survivin

Okamoto, K., Okamoto, I., Hatashita, E., Kuwata, K., Yamaguchi, H., Kita, A., Yamanaka, K., Ono, M. & Nakagawa, K., Jan 1 2012, In : Molecular Cancer Therapeutics. 11, 1, p. 204-213 10 p.

Research output: Contribution to journalArticle

Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Mutation
Protein-Tyrosine Kinases
Apoptosis
5 Citations (Scopus)

Perirenal hematoma associated with bevacizumab treatment

Hayashi, H., Okamoto, I. & Nakagawa, K., Apr 1 2012, In : Investigational New Drugs. 30, 2, p. 808-809 2 p.

Research output: Contribution to journalArticle

Hematoma
Therapeutics
Hemorrhage
Drug Therapy
Rectal Neoplasms
1 Citation (Scopus)

Pharmacokinetics of docetaxel in a patient with non-small cell lung cancer undergoing continuous ambulatory peritoneal dialysis

Kaneda, H., Okamoto, I. & Nakagawa, K., Jan 1 2012, In : Journal of Thoracic Oncology. 7, 3, p. 621-622 2 p.

Research output: Contribution to journalArticle

docetaxel
Taxoids
Continuous Ambulatory Peritoneal Dialysis
Tissue Distribution
Non-Small Cell Lung Carcinoma
8 Citations (Scopus)

Phase I clinical study of the angiogenesis inhibitor TSU-68 combined with carboplatin and paclitaxel in chemotherapy-naive patients with advanced non-small cell lung cancer

Okamoto, I., Yoshioka, H., Takeda, K., Satouchi, M., Yamamoto, N., Seto, T., Kasahara, K., Miyazaki, M., Kitamura, R., Ohyama, A., Hokoda, N., Nakayama, H., Yoshihara, E. & Nakagawa, K., Jan 1 2012, In : Journal of Thoracic Oncology. 7, 2, p. 427-433 7 p.

Research output: Contribution to journalArticle

Angiogenesis Inhibitors
Carboplatin
Paclitaxel
Non-Small Cell Lung Carcinoma
Drug Therapy
48 Citations (Scopus)

Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer

Hayashi, H., Okamoto, I., Morita, S., Taguri, M. & Nakagawa, K., Jun 6 2012, In : Annals of Oncology. 23, 6, p. 1537-1541 5 p.

Research output: Contribution to journalArticle

Non-Small Cell Lung Carcinoma
Drug Therapy
Survival
Disease-Free Survival
8 Citations (Scopus)

Reversible posterior leukoencephalopathy syndrome and trastuzumab

Kaneda, H., Okamoto, I., Satoh, T. & Nakagawa, K., Aug 1 2012, In : Investigational New Drugs. 30, 4, p. 1766-1767 2 p.

Research output: Contribution to journalArticle

Posterior Leukoencephalopathy Syndrome
Hypertension
Stomach Neoplasms
Brain
Vascular Endothelial Growth Factor A
10 Citations (Scopus)

Safety and pharmacokinetic study of nab-paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer

Okamoto, I., Yamamoto, N., Kubota, K., Ohe, Y., Nogami, N., Murakami, H., Yamaya, H., Ono, K. & Nakagawa, K., Jun 1 2012, In : Investigational New Drugs. 30, 3, p. 1132-1137 6 p.

Research output: Contribution to journalArticle

Carboplatin
Non-Small Cell Lung Carcinoma
Nanoparticles
Pharmacokinetics
Area Under Curve
22 Citations (Scopus)

SRPX2 is a novel chondroitin sulfate proteoglycan that is overexpressed in gastrointestinal cancer

Tanaka, K., Arao, T., Tamura, D., Aomatsu, K., Furuta, K., Matsumoto, K., Kaneda, H., Kudo, K., Fujita, Y., Kimura, H., Yanagihara, K., Yamada, Y., Okamoto, I., Nakagawa, K. & Nishio, K., Jan 5 2012, In : PloS one. 7, 1, e27922.

Research output: Contribution to journalArticle

sushi
Chondroitin Sulfate Proteoglycans
chondroitin sulfate
Gastrointestinal Neoplasms
proteoglycans
5 Citations (Scopus)

Successful long-term treatment with pemetrexed of NSCLC associated with EML4-ALK and low thymidylate synthase expression

Takeda, M., Okamoto, I., Sakai, K., Tanaka, K., Terashima, M., Nishio, K. & Nakagawa, K., Mar 2012, In : Clinical Lung Cancer. 13, 2, p. 157-159 3 p.

Research output: Contribution to journalArticle

Fusion Oncogene Proteins
Pemetrexed
Pleural Neoplasms
Signet Ring Cell Carcinoma
Glutamates
381 Citations (Scopus)

Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: Final results of a phase III trial

Socinski, M. A., Bondarenko, I., Karaseva, N. A., Makhson, A. M., Vynnychenko, I., Okamoto, I., Hon, J. K., Hirsh, V., Bhar, P., Zhang, H., Iglesias, J. L. & Renschler, M. F., Jun 10 2012, In : Journal of Clinical Oncology. 30, 17, p. 2055-2062 8 p.

Research output: Contribution to journalArticle

Carboplatin
Paclitaxel
Non-Small Cell Lung Carcinoma
Histology
Therapeutics
2011
327 Citations (Scopus)

Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab

Yonesaka, K., Zejnullahu, K., Okamoto, I., Satoh, T., Cappuzzo, F., Souglakos, J., Ercan, D., Rogers, A., Roncalli, M., Takeda, M., Fujisaka, Y., Philips, J., Shimizu, T., Maenishi, O., Cho, Y., Sun, J., Destro, A., Taira, K., Takeda, K., Okabe, T. & 12 others, Swanson, J., Itoh, H., Takada, M., Lifshits, E., Okuno, K., Engelman, J. A., Shivdasani, R. A., Nishio, K., Fukuoka, M., Varella-Garcia, M., Nakagawa, K. & Jänne, P. A., Sep 7 2011, In : Science Translational Medicine. 3, 99

Research output: Contribution to journalArticle

Antibodies
Neuregulin-1
Therapeutics
Mitogen-Activated Protein Kinase 3
Mitogen-Activated Protein Kinase 1

Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab.

Yonesaka, K., Zejnullahu, K., Okamoto, I., Satoh, T., Cappuzzo, F., Souglakos, J., Ercan, D., Rogers, A., Roncalli, M., Takeda, M., Fujisaka, Y., Philips, J., Shimizu, T., Maenishi, O., Cho, Y., Sun, J., Destro, A., Taira, K., Takeda, K., Okabe, T. & 12 others, Swanson, J., Itoh, H., Takada, M., Lifshits, E., Okuno, K., Engelman, J. A., Shivdasani, R. A., Nishio, K., Fukuoka, M., Varella-Garcia, M., Nakagawa, K. & Jänne, P. A., Sep 7 2011, In : Science Translational Medicine. 3, 99

Research output: Contribution to journalArticle

Antibodies
Neuregulin-1
Therapeutics
Mitogen-Activated Protein Kinase 3
Mitogen-Activated Protein Kinase 1